What type of study is this?

August 20, 2025Open Access

First experience of Russian-manufactured generic nusinersen treatment in pediatric SMA patients

Key Points

The Russian-manufactured generic nusinersen showed a positive effect on motor activity in all patients treated.
Motor development scales revealed improved motor function across five clinical cases involving diverse SMA types.
Assessment of the generic nusinersen treatment demonstrated both efficacy and a favorable safety profile overall.
Clinical scenarios included both naive patients and those transitioning from the reference nusinersen drug.

Abstract

Currently, Russian-manufactured generic products are being actively implemented into the clinical practice in the Russian Federation, including spinal muscular atrophy treatment. This article presents five clinical cases with various types of spinal muscular atrophy treatment with generic Russian nusinersen, both naive and those who had previously received therapy with the reference drug nusinersen and continued therapy with generic nusinersen. The trend in motor activity in patients during treatment, assessed by motor development scales, is presented. In all of 5 described clinical cases both the positive effect and favorable safety profile of the Russian-manufactured generic nusinersen were demonstrated.

Read Full Paperexternally

Ask AI

Helpful

Bookmark

View Full Paper